header
Image from OpenLibrary

Low bose cytarabine with or without anthracycline in the induction treatment of elderly patients with acute myeloid leukemia / Ahmad Abdel Raheem Ahmad Abdel Raheem ; Supervised Fouad M. Abu-Taleb , Osman M. Mansour , Nahla El Sharkawy

By: Contributor(s): Material type: TextTextLanguage: English Publication details: Cairo : Ahmad Abdelraheem Ahmad Abdelraheem , 2011Description: 187 P. : charts ; 25cmOther title:
  • الجرعات المنخفضة من عقار السيتارابين مع أو بدون عقار الانثراسيكلين كعلاج مبدني لكبار السن من مرضى سرطان الدم الميلودى الحاد [Added title page title]
Subject(s): Available additional physical forms:
  • Issued also as CD
Dissertation note: Thesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Oncology-Medical Summary: Acute myelogenous leukemia is a disease of the elderly with median age at diagnosis 60 years, despite an improved molecular understanding of AML, treatment has been largely unsuccessful in the population age 60 and older with most patients dying within one year of diagnosis. To compare the outcome of elderly AML patients receiving low dose cytarabine (LDAC) plus doxorubicin versus low dose cytarabine to identify which one is more suitable for elderly AML patient regarding response rate
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Home library Call number Copy number Status Date due Barcode
Thesis Thesis قاعة الرسائل الجامعية - الدور الاول المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.19.04.Ph.D.2011.Ah.L (Browse shelf(Opens below)) Not for loan 01010110055192000
CD - Rom CD - Rom مخـــزن الرســائل الجـــامعية - البدروم المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.19.04.Ph.D.2011.Ah.L (Browse shelf(Opens below)) 55192.CD Not for loan 01020110055192000

Thesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Oncology-Medical

Acute myelogenous leukemia is a disease of the elderly with median age at diagnosis 60 years, despite an improved molecular understanding of AML, treatment has been largely unsuccessful in the population age 60 and older with most patients dying within one year of diagnosis. To compare the outcome of elderly AML patients receiving low dose cytarabine (LDAC) plus doxorubicin versus low dose cytarabine to identify which one is more suitable for elderly AML patient regarding response rate

Issued also as CD

There are no comments on this title.

to post a comment.